Improving biophysical properties of a bispecific antibody scaffold to aid developability (Q27679445)

1

0 references

Eric Escobar-Carbrera

2

0 references

Paula I Lario

3

0 references

Igor D'Angelo

4

0 references

Karine Brault

5

0 references

John Kelly

6

0 references

Yves Durocher

7

0 references

Jason Baardsnes

8

0 references

R Jeremy Woods

9

0 references

Michael Hongwei Xie

10

0 references

Pierre-Alain Girod

11

0 references

Michael D L Suits

12

0 references

Martin J Boulanger

13

0 references

David K Y Poon

14

0 references

Gordon Y K Ng

15

0 references

Surjit B Dixit

16

0 references

language of work or name

English

0 references

publication date

2013

1 reference

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

published in

Monoclonal Antibodies

0 references

volume

5

0 references

issue

5

0 references

page(s)

646-54

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Folding and association of the antibody domain CH3: prolyl isomerization preceeds dimerization

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Comparison of multiple Amber force fields and development of improved protein backbone parameters

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Dual targeting strategies with bispecific antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Forced degradation of therapeutic proteins.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Introduction to current and future protein therapeutics: a protein engineering perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Prediction of immunogenicity of therapeutic proteins: validity of computational tools

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Antibody therapeutics, antibody engineering, and the merits of protein stability

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Considerations for the development of therapeutic monoclonal antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

The backrub motion: how protein backbone shrugs when a sidechain dances

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Specificity versus stability in computational protein design

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Protein aggregation and its inhibition in biopharmaceutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Folding mechanism of the CH2 antibody domain.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Extending the accuracy limits of prediction for side-chain conformations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Bispecific human IgG by design

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

An efficient route to human bispecific IgG.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Empirical potentials and functions for protein folding and binding.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

Contribution of domain interface residues to the stability of antibody CH3 domain homodimers.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851217

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

2 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

A broad range of Fab stabilities within a host of therapeutic IgGs.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Folding and oxidation of the antibody domain C(H)3.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Bispecific antibodies and ADCs: Once and future kings?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

LC-MS characterization and purity assessment of a prototype bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25632

Introduction: bispecific antibodies

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23924797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/23924797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Estimation of protein aggregation propensity with a melting point apparatus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23924797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/MABS.25632

1 reference

3103224

3103224

1 reference

1 reference

1 reference